Key Takeaways
- The telehealth company boosted its 2026 revenue forecast to $3.1B-$3.3B, significantly exceeding analysts’ $2.93B projection
- Second-quarter revenue reached $753.2M, surpassing expectations, but the firm reported a $0.37-per-share loss compared to the anticipated $0.05 loss
- Shares of HIMS dropped approximately 7% during Tuesday’s premarket session following a 5.5% decline in after-hours trading Monday
- The company experienced its fourth consecutive quarter of margin compression as expenses climbed, with total operational expenses jumping 48% compared to last year
- Ongoing restructuring expenses are expected as the business transitions away from compounded GLP-1 medications toward FDA-approved branded weight-loss treatments
Despite delivering a significantly improved 2026 revenue outlook that exceeded Wall Street’s projections on Monday, Hims & Hers Health couldn’t convince investors to stick around. The company’s shares plummeted 5.5% during after-hours trading and continued sliding nearly 7% in Tuesday’s premarket session.
Hims & Hers Health, Inc., HIMS
Management revised its full-year revenue projection upward to a range of $3.1 billion to $3.3 billion, representing an increase from the previous forecast of $2.8 billion to $3 billion. The third-quarter outlook of $880 million to $900 million similarly topped analyst expectations of $792.2 million.
Second-quarter sales totaled $753.2 million, exceeding the FactSet consensus estimate of $698.9 million. During the same period, the platform gained over 300,000 new subscribers.
However, the positive top-line figures couldn’t obscure deeper profitability concerns. The business reported a per-share loss of $0.37, substantially wider than the $0.05 loss that Wall Street had projected.
Overall operational expenses skyrocketed 48% year-over-year. Revenue costs more than doubled, reaching $272.4 million, resulting in gross margin compression for the fourth quarter in a row.
Chief Financial Officer Yemi Okupe addressed the margin situation directly during the analyst call. He indicated that gross margins would probably remain under historical benchmarks as branded weight-management products and international operations constitute a larger portion of the revenue mix.
GLP-1 Strategy Shift Drives Margin Headwinds
The expense narrative connects directly to Hims’ strategic pivot away from compounded GLP-1 treatments. The organization had rapidly expanded its weight-loss segment by offering compounded semaglutide during the supply constraints affecting Wegovy and Zepbound, but that era is coming to an end.
Back in March, Hims agreed to discontinue manufacturing its compounded GLP-1 medications following a patent infringement action brought by Novo Nordisk. The business is now transitioning toward distributing FDA-approved brand-name alternatives, a change that brings substantially higher cost structures.
Management indicated that restructuring-related expenses tied to this operational transition would continue. The company lowered the upper range of its adjusted EBITDA forecast for the year, even while lifting revenue guidance.
Leerink Partners analyst Michael Cherny captured the challenge: “We still see a tough balance between spending to grow and growth, keeping our optimism limited.”
Litigation Expenses Compound Financial Strain
In addition to margin challenges, Hims recorded $47.5 million in nonrecurring contingency expenses during the quarter. These reserves represent anticipated settlements related to ongoing legal matters.
Among these cases is a lawsuit initiated just over a week ago by the Federal Trade Commission alongside multiple state attorneys general, alleging misleading privacy practices, undisclosed billing tactics, and creating obstacles for subscription cancellations. The company rejected these allegations as attempts “to generate headlines at our expense.”
Chief Executive Andrew Dudum devoted considerable attention during his remarks to the company’s newly developed AI clinical platform, which he believes is transforming the consumer healthcare landscape. CFO Okupe attributed the improved guidance to AI-powered operational improvements and expanding international presence, including the purchase of Australian telehealth provider Eucalyptus.
Barclays analyst Glen Santangelo suggested margin recovery could materialize during the year’s second half. The company has established long-term targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.
Year-to-date, HIMS stock has declined approximately 2%.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
